Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Astellas Pharma Inc
(OP:
ALPMF
)
12.18
+1.28 (+11.74%)
Streaming Delayed Price
Updated: 9:30 AM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Astellas Pharma Inc
< Previous
1
2
Next >
Small-Cap Cancer-Focused Nuvation Bio Pulls Plug On Early-Stage Program After Considering Phase 1 Solid Tumor Data
August 05, 2024
Nuvation Bio halts its NUV-868 BET inhibitor program after Phase 1 study analysis. The decision impacts solid tumor treatments in ovarian, pancreatic, and mCRPC cancers, focusing instead on late-stage...
Via
Benzinga
Bayer Highlights Detailed Data From Twin Late-Stage Trials On Experimental Menopause Candidate, Seeks Regulatory Approval
May 17, 2024
Bayer to present detailed Phase 3 OASIS 1 and 2 study results showing elinzanetant significantly reduces moderate to severe menopausal vasomotor symptoms compared to placebo.
Via
Benzinga
Merck's Best Selling Cancer Drug Meets One Goal In Late-Stage Bladder Cancer Study
October 05, 2023
Merck & Co Inc (NYSE: MRK) announced that the Phase 3 AMBASSADOR (A031501) trial (KEYNOTE-123) evaluating Keytruda met one of its dual primary endpoints of disease-free survival for the adjuvant...
Via
Benzinga
Why Is Seagen Stock Trading Higher Today?
September 22, 2023
Seagen Inc (NASDAQ: SGEN) and Astellas Pharma Inc (OTC: ALPMF) (OTC:
Via
Benzinga
What's Going On With Neurology Focused Taysha Gene Therapies Stock Today?
September 20, 2023
Astellas Pharma Inc (OTC: ALPMY) (OTC: ALPMF) has elected
Via
Benzinga
Astellas' Menopause Drug Under FDA Review
August 18, 2022
Via
Benzinga
Seagen's Bladder Cancer Trial Data Meets Expectation, Analysts Say
July 26, 2022
Via
Benzinga
Sutro Biopharma Stock Surges On Cancer Treatment Pact
June 28, 2022
Via
Benzinga
Why Shares of Adaptive Biotechnologies Jumped This Week
June 16, 2023
The company could see its first FDA-approved therapy as early as next year.
Via
The Motley Fool
Astellas Pharma Licenses Promising Gene Therapy KT430 from Kate Therapeutics Amidst Clinical Hurdles
June 08, 2023
Astellas Pharma Inc (OTC: ALPMF) (OTC: ALPMY) decided to license and advance a gene therapy from Kate Therapeutics for a debilitating muscle disorder known as
Via
Benzinga
Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition?
June 01, 2023
By David Willey, Benzinga
Via
TheNewswire.com
Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition?
June 01, 2023
Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition?
Via
News Direct
Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition?
May 30, 2023
The Japanese healthcare company Astellas Pharma, Inc. (OTC: ALPMF) recently announced its acquisition of the biopharmaceutical company Iveric Bio
Via
Benzinga
Astellas's Pompe Disease Gene Therapy Trial Put On FDA Clinical Hold
June 27, 2022
Via
Benzinga
Google Launches Tools To Detect Fake Images, Apple May Encounter Delays In iPhone 15 Production, Shake Shack Sees Activist Investor Proxy Fight: Today's Top Stories
May 15, 2023
Bloomberg
Via
Benzinga
Astellas' Menopause Drug Sores FDA Approval, After Regulatory Setback
May 15, 2023
The FDA on Friday approved Japanese drugmaker Astellas Pharma Inc’s (OTC: ALPMY) (OTC: ALPMF) Veozah (fezolinetant) for hot flashes
Via
Benzinga
Pfizer, Astellas' Xtandi Combo Therapy Cuts Risk Of Metastasis, Death In Prostate Cancer By 58%
May 01, 2023
Astellas Pharma Inc (OTC: ALPMY) and Pfizer Inc (NYSE: PFE) announced
Via
Benzinga
Astellas Pharma Acquires Iveric Bio For $5.9B To Focus On 'Blindness & Regeneration'
May 01, 2023
Japanese healthcare company Astellas Pharma Inc (OTC: ALPMY) has agreed to buy Iveric Bio Inc (NASDAQ: ISEE) for $40.00 per share in cash for a total equity value of
Via
Benzinga
FDA Approves Merck's Keytruda Combined With Seagen/Astellas's Padcev For Advanced Urothelial Cancer
April 04, 2023
Via
Benzinga
AbbVie Walks Away From CytomX Partnership, But Garnering Attention Of Big Pharma Partners
March 28, 2023
Via
Benzinga
Japanese Government Urges China To Release Astellas Pharma's Employee
March 27, 2023
The Japanese government is reportedly seeking the release of an employee of Japanese pharma company Astellas Pharma Inc (OTC: ALPMF), detained by Chinese authorities. The reasons why the person was...
Via
Benzinga
Pfizer, Astellas Tout Positive Xtandi Data To Potentially Expand Label For The Prostate Cancer Drug
March 17, 2023
Via
Benzinga
Analyst Says Selecta Biosciences' Gout Candidate Can Potentially Raise The Bar On Several Fronts
January 31, 2023
Via
Benzinga
Sandoz Acquires Antifungal Agent From Astellas, Reinforcing Hospital Offering
January 24, 2023
Via
Benzinga
Astellas Pharma Invests $50M To Support Taysha's Gene Therapy Programs
October 25, 2022
Via
Benzinga
Daily Biotech Pulse: EU Approval For AbbVie's Ulcerative Colitis Treatment, Angion Biomedica Evaluates Alternatives, Clinical Hold For Immuron's Bacterial Infection Candidate
July 26, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Seagen Shares Jump On Positive Data From Urothelial Cancer Trial
July 26, 2022
Via
Benzinga
The Daily Biotech Pulse: Kezar Life Surges On Positive Kidney Disease Trial Data, FDA Rejects Spero Therapeutics' Tebipenem, Graybug Reviews Strategic Alternatives
June 28, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies
June 27, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Twist Bioscience, Astellas Join Forces To Develop Cancer Targeting Antibodies
May 09, 2022
Via
Benzinga
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.